Share

Abacus Medicine Pharma Services (AMPS) and Laboratoires CTRS, marketing authorization holder of Orphacol庐, are proud to announce a strategic partnership that ensures continuous stock of Orphacol庐 in Spain. Furthermore, the partnership means improved delivery lead times for customers as well as implementation of simplified sales, distribution, and administration processes for Laboratoires CTRS, thus saving individual deliveries and the associated administration.

Orphacol庐 is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats.

It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. Orphacol is used in patients who do not have enough of two specific liver enzymes (3尾-hydroxy-螖5-C27-steroid oxidoreductase or 螖4-3-oxosteroid-5尾-reductase). This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains:

鈥淚 am very proud of the partnership agreement between Abacus Medicine Pharma Services and Laboratoires CTRS. Our ambition is to provide better access to medicines and better healthcare to patients around the world. This partnership with Laboratoires CTRS will ensure reliable availability to Orphacol 庐 in Spain at all times, as well as improved delivery time for customers.鈥

Franck Hamalian, President of Laboratoires CTRS states:

鈥淲ith this partnership, CTRS and AMPS, reduce lead time for delivery and further enhance availability of Orphacol庐 for patients in need on the Spanish territory. We know this to be a factor of highest importance for the life-saving treatment that is Orphacol庐 and are glad to join forces with such a robust and growing actor as AMPS.鈥

3尾-hydroxy-螖5-C27-steroid oxidoreductase or 螖4-3-oxosteroid-5尾-reductase deficiencies are part of are a group of Bile Acid Synthesis Disorders (BASD) which are rare metabolic diseases caused by a lack of various liver enzymes involved in the synthesis of bile acids. This makes the liver unable to produce enough of the main components of bile such as cholic acid. BASD are responsible for 1-2% of cases of neonatal cholestasis that occurs in approximately 1 in 2,500 births and is the main cause of liver-related paediatric hospitalisations, as well as 80% of paediatric liver transplantations.

Product information

  • Orphacol庐 film-coated tablets 30 pcs. 250mg (C贸digo nacional: 7048480)
  • Orphacol庐 film-coated tablets 30 pcs. 50mg (C贸digo nacional: 7048756)